(Hikari Fund’s Portfolio)

Cytovale is a team of biologists, data scientists, and engineers developing mechanical biomarkers to improve human health. Their novel microfluidic platform allows them to probe individual cells to quantify the mechanical signatures of disease. They are applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes and reduces treatment cost.